ShanXi C&Y Pharmaceutical Group Co.,LTD. (SHE:300254)
China · Delayed Price · Currency is CNY 7.54
-0.14 (-1.82%)
Jul 30, 2026, 3:04 PM CST
SHE:300254 Financials Overview
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Revenue Revenue Growth | 862.85 | 870.79 | 846.61 | 799.31 | 829 | 930.37 |
Revenue Growth | 2.86% | 2.86% | 5.92% | -3.58% | -10.90% | 9.71% |
Gross Profit Gross Profit Growth | 575.63 | 585.54 | 563.39 | 539.86 | 577.79 | 640.32 |
Operating Income Operating Income Growth | 103.9 | 109.06 | 73.04 | 32.02 | -23.64 | -28.16 |
Net Income Net Income Growth | 17.8 | 24.85 | 42.19 | 25.2 | -118.52 | -91.44 |
Earnings Per Share EPS Growth | 0.07 | 0.10 | 0.17 | 0.10 | -0.50 | -0.40 |
EPS Growth | -48.81% | -41.77% | 67.11% | - | - | - |
| Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Medicine Medicine Growth | 812.91 | 818.46 | 752.33 | 779.85 | 874.34 |
Health Food Health Food Growth | 6.48 | 6.65 | 12.54 | 10.73 | 16.13 |
Services Services Growth | 11.25 | 16.37 | 26.76 | 33.8 | 33.79 |
Business Business Growth | 37.53 | 0.84 | 0.79 | 0.46 | 0.69 |
Unallocated Other Business Unallocated Other Business Growth | 2.62 | 4.28 | 6.89 | 4.15 | 5.43 |
Total Total Growth | 870.79 | 846.61 | 799.31 | 829 | 930.37 |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Cash & Investments Cash & Investments Growth | 137.61 | 161.32 | 149.52 | 132 | 263.95 | 107.26 |
Total Debt Total Debt Growth | 571.71 | 401.72 | 456.92 | 226.22 | 288.92 | 229.59 |
Net Cash (Debt) Net Cash Growth | -434.1 | -240.4 | -307.41 | -94.21 | -24.97 | -122.33 |
Net Cash Growth | - | - | - | - | - | - |
Net Cash Per Share Net Cash Per Share Growth | -1.77 | -0.98 | -1.27 | -0.39 | -0.11 | -0.54 |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Cash Flow Operating Cash Flow Growth | 112.71 | 96.77 | 70.94 | 37.81 | 74.88 | 96.92 |
Capital Expenditures CapEx Growth | -33.08 | -34.32 | -51.5 | -33.92 | -26.78 | -36.93 |
Free Cash Flow Free Cash Flow Growth | 79.63 | 62.45 | 19.44 | 3.9 | 48.09 | 59.99 |
Free Cash Flow Growth | 200.81% | 221.25% | 398.72% | -91.90% | -19.84% | - |
| Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Gross Margin | 66.71% | 67.24% | 66.55% | 67.54% | 69.70% | 68.82% |
Operating Margin | 12.04% | 12.52% | 8.63% | 4.00% | -2.85% | -3.03% |
Pretax Margin | 9.50% | 10.43% | 9.53% | 6.92% | -10.86% | -7.04% |
Profit Margin | 2.06% | 2.85% | 4.98% | 3.15% | -14.30% | -9.83% |
FCF Margin | 9.23% | 7.17% | 2.30% | 0.49% | 5.80% | 6.45% |
| Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Period Ending | Jul '26 Jul 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
PE Ratio | 104.15 | 104.30 | 51.50 | 92.35 | - | - |
Forward PE | - | 47.48 | 47.48 | 47.48 | 47.48 | 47.48 |
P/FCF Ratio | 24.25 | 41.50 | 111.77 | 596.91 | 34.01 | 33.02 |
PS Ratio | 2.24 | 2.98 | 2.57 | 2.91 | 1.97 | 2.13 |